1-(4,5-dihydrothiazol-2-yl)-3-phenylurea, also known as **Dithiazanine**, is a **synthetic thiazole derivative** with a variety of applications in research.
**Structure and Properties:**
* It is a white crystalline solid with a molecular weight of 237.29 g/mol.
* Its structure features a thiazole ring with a phenylurea substituent.
**Research Applications:**
Dithiazanine is primarily used in research for its ability to:
* **Interact with DNA:** It exhibits fluorescence upon binding to DNA, making it a useful **DNA probe** for studying DNA structure, interactions, and dynamics.
* **Inhibit enzymes:** It is known to inhibit certain enzymes, particularly those involved in **DNA replication** and **cell division**. This property has made it a potential target for **anticancer drug development**.
* **Induce apoptosis:** In certain cell types, Dithiazanine can trigger programmed cell death (apoptosis). This has led to investigations into its use as an **anti-cancer agent**.
* **Study ion channels:** It can interact with ion channels, particularly **potassium channels**, making it a valuable tool for investigating their function and regulation.
* **Investigate membrane properties:** Its ability to interact with cell membranes has also made it useful for studying membrane permeability and fluidity.
**Other Applications:**
* **Fluorescent dye:** Due to its fluorescence properties, Dithiazanine has been used as a **fluorescent dye** in microscopy and other analytical techniques.
* **Antiparasitic agent:** It has shown some activity against certain parasites, particularly those affecting livestock.
**Importance in Research:**
Dithiazanine's versatility makes it a valuable tool in a wide range of research areas. Its ability to interact with DNA, enzymes, ion channels, and cell membranes provides insights into fundamental biological processes and has paved the way for potential applications in medicine and agriculture.
**Note:** While Dithiazanine has potential as a drug candidate, further research is needed to optimize its properties and ensure its safety and effectiveness for therapeutic use.
ID Source | ID |
---|---|
PubMed CID | 773295 |
CHEMBL ID | 1371455 |
CHEBI ID | 109356 |
Synonym |
---|
1-(4,5-dihydro-1,3-thiazol-2-yl)-3-phenylurea |
smr000019276 |
n-4,5-dihydro-1,3-thiazol-2-yl-n'-phenylurea |
MLS000084930 |
CHEBI:109356 |
AKOS003623192 |
HMS2355E12 |
CHEMBL1371455 |
1-(4,5-dihydrothiazol-2-yl)-3-phenylurea |
Q27188456 |
sr-01000150118 |
SR-01000150118-1 |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 12.6886 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 1.2589 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 5.9593 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
pyruvate kinase | Leishmania mexicana mexicana | Potency | 25.1189 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.4125 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 12.9244 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.4125 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
snurportin-1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 10.0000 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 0.8913 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 5.0119 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Integrin beta-3 | Homo sapiens (human) | Potency | 10.0000 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Integrin alpha-IIb | Homo sapiens (human) | Potency | 10.0000 | 0.3162 | 11.4157 | 31.6228 | AID924 |
Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |